Supplemental Data: e-References
e-1.Bots ML, Elwood PC, Salonen JT, et al. Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002; 56 Suppl 1:i14–88.
e-2.Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA2005; 294:1799–1809.
e-3.Sato S, Iso H, Noda H, et al. Plasma fibrinogen concentrations and risk of stroke and its subtypes among Japanese men and women. Stroke 2006; 37:2488–2492.
e-4.Lammie GA. Pathology of small vessel stroke. Br. Med. Bull 2000; 56:296–306.
e-5.Fisher CM. Lacunar infarcts: a review. Cerebrovasc.Dis1991; 1:311–320.
e-6.Tatsumi S, Shinohara M, Yamamoto T. Direct Comparison of Histology of Microbleeds with Postmortem MR Images.Cerebrovasc. Dis2008; 26:142–146.
e-7.Khan U, Porteous L, Hassan A, Markus HS.Risk factor profile of cerebral small vessel disease and its subtypes.J NeurolNeurosurgPsychiatr2006; 78:702–706.
e-8.Hassan A. Markers of endothelial dysfunction in lacunar infarction and ischaemicleukoaraiosis.Brain2003; 126:424–432.
e-9.Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics--2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2007; 115:e69–e171.
e-10.Fielden SJ, Rusch MLA, Yip B, et al. Nonadherence Increases the Risk of Hospitalization Among HIV-Infected Antiretroviral Naive Patients Started on HAART. Journal of the International Association of Physicians in AIDS Care2008; 7:238–244.
e-11.Kuyper LM, Wood E, Montaner JSG, Yip B, O'connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.J Acquir Immune DeficSyndr 2004; 37:1470–1476.
e-12.Bonolo PF, Ceccato MG, Rocha GM, Acurcio FA, Campos LN, Guimaraes MD.Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy.Clinics2013; 68:612–620.
e-13.Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med 2010; 11:299–307.
e-14.Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level. J Acquir Immune DeficSyndr 2010; 55:460–465.
e-15.Yuan Y, L'italien G, Mukherjee J, Iloeje UH.Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.HIVMed2006; 7:156–162.
e-16.Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1. Nature Publishing Group 2010; 1–6.
e-17.Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. J Infect Dis2013; 208:1737–1746.
e-18.Torres TS, Cardoso SW, de Souza Velasque L, et al. Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Brazilian Journal of Infectious Diseases2013; 17:324–331.
e-19.Hasse B, Ledergerber B, Furrer H, et al. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. Clin Infect Dis2011; 53:1130–1139.
e-20. Centers for Disease Control and Prevention CDC. HIV prevalence estimates--
United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1073–
1076.